Physician profile
Robert A Moraru
NPI 1285705061
$12,607.80
in general payments reported to CMS, 2019-2025
42 companies · $2,029 in 2025
The $2,029 reported for 2025 was more than what 76% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,383 · 2020: $920 · 2021: $1,449 · 2022: $1,769 · 2023: $1,937 · 2024: $2,121 · 2025: $2,029.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,669 · Education: $419.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,668.93 |
| Education | $418.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,945.81 | 2019-2025 | Tremfya |
| Abbvie INC. | $1,575.04 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $753.29 | 2019-2025 | Dupixent |
| Amgen INC. | $702.65 | 2019-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $638.03 | 2019-2021 | |
| Lilly USA, LLC | $576.32 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Pfizer INC. | $555.75 | 2019-2025 | |
| Leo Pharma INC. | $552.99 | 2019-2025 | Adbry, Anzupgo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $517.45 | 2019-2025 | Jublia, Cabtreo, Arazlo |
| Galderma Laboratories, L.P. | $420.38 | 2019-2025 | Nemluvio |
| Genzyme Corporation | $412.69 | 2021-2025 | |
| Dermavant Sciences, INC. | $376.55 | 2022-2024 | Vtama |
| Mayne Pharma Commercial LLC | $364.16 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $310.35 | 2019-2025 | |
| Celgene Corporation | $222.13 | 2019 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Moraru listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.